SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

1 marketing jobs

AbbVie logo
4 days ago

Omnichannel Campaign Manager

AbbVie

Illinois, USA (On-site)Full time$110K/yr – $209K/yr

Find marketing roles you could actually win

1 open roles0

Popular searches:

Growth MarketingHead of MarketingSEO ManagerProduct MarketingPaid MediaBrand Manager
Growth MarketingHead of MarketingPerformance MarketingContent StrategySEO ManagerProduct MarketingDemand GenerationBrand ManagerPaid MediaMarketing AnalyticsCRM ManagerSocial Media

Find marketing roles you could actually win

1 open roles0

Popular searches:

Growth MarketingHead of MarketingSEO ManagerProduct MarketingPaid MediaBrand Manager
Growth MarketingHead of MarketingPerformance MarketingContent StrategySEO ManagerProduct MarketingDemand GenerationBrand ManagerPaid MediaMarketing AnalyticsCRM ManagerSocial Media
1 jobs
AbbVie logo

Omnichannel Campaign Manager

AbbVie

Illinois, USA (On-site)

$110K/yr - $209K/yrIn-houseFull-timeSenior level5+ years exp.
4 days ago
AbbVie logo
AbbVie

Omnichannel Campaign Manager

Illinois, USA (On-site)

$110K/yr – $209K/yrSenior Level5+ years expFull time

Posted 4 days ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Own end-to-end Digital Lab campaign execution across omnichannel channels, coordinating cross-functional teams and partners to deliver compliant, optimized marketing programs while managing plans, risks, and process improvements.

  • Lead implementation plans and timelines for assigned campaigns
  • Manage day-to-day progress, blockers, and risks
  • Partner with Marketing Operations and cross-functional teams to optimize processes

Job Description

Responsibilities

  • Manage Digital Lab execution of assigned brand omnichannel campaigns, ensuring seamless implementation, timely delivery, and risk mitigation
  • Develop and maintain detailed implementation plans, roadmaps, and timelines for assigned campaigns across Digital Lab channels
  • Drive day-to-day campaign progress, monitoring dependencies, proactively resolving roadblocks, and managing risks
  • Identify changes in scope, risks, and issues, escalating or implementing corrective actions as needed
  • Coordinate with cross-functional Digital Lab teams, Business Technology Services (BTS), APEX (where appropriate), and digital agency partners to ensure execution excellence
  • Utilize Smartsheets and other project management tools to track campaign status, milestones, and deliverables
  • Support evaluation of campaign implementation effectiveness to identify efficiency improvements and lessons learned
  • Contribute to process standardization by following established playbooks, implementation guides, and RACI models
  • Champion automation efficiency initiatives and adopt AI tools and advanced project management platforms
  • Partner with Marketing Operations on project management technology usage and optimization

Requirements

  • Bachelor's degree in Marketing, Business Administration, Communications, or related field
  • 5+ years of experience in campaign management, project management, or marketing operations, preferably within pharmaceutical, healthcare, or regulated industries
  • Demonstrated experience managing multi-channel marketing campaigns with cross-functional teams
  • Proficiency in project management tools such as Smartsheet, Adobe Workfront, Asana, or similar platforms
  • Strong understanding of digital marketing channels including email, web, social, and display advertising
  • Experience working in matrixed organizations with multiple stakeholders
  • Excellent organizational skills with ability to manage multiple campaigns simultaneously
  • Strong communication and interpersonal skills with ability to build effective working relationships
  • Detail-oriented with strong problem-solving abilities

Preferred

  • Experience in pharmaceutical or healthcare marketing
  • Knowledge of medical/legal review processes for promotional materials
  • Familiarity with CRM systems and marketing automation platforms
  • Experience with Agile or other project management methodologies
  • Exposure to AI-driven project management tools
  • Understanding of creative agency processes and workflows
  • Key Competencies: Campaign execution and project management
  • Cross-functional coordination and collaboration
  • Attention to detail and process adherence
  • Proactive problem-solving and risk management

Benefits

  • We offer a comprehensive package of benefits including paid time off (vacation, holidays, sick), medical/dental/vision insurance and 401(k) to eligible employees.
AbbVie logo

AbbVie

4.0 Glassdoor

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Founded in 2013
North Chicago, Illinois, USA
60K employees (3,267 in marketing)
www.abbvie.com
78% recommend to a friend
88% CEO approval

Salaries

Posted range

$110K/yr – $209K/yr

Taken straight from the job posting.

See all AbbVie salaries

Marketing Team

Marketing Team Size
2,942 (5% of company)
Median Career Experience
18 years
Median Tenure
7.5 years
Marketing Roles Posted (Last 30 Days)
29

People

HR / Recruitment

Shavonne Thomas
Shavonne Thomas
Associate Director, Employer Brand & Recruitment Marketing
At the company for 4 years 1 month
Erin Lattin, SHRM-SCP
Erin Lattin, SHRM-SCP
Director, Business HR - International Marketing and Commercial Operations
At the company for 5 years 2 months

Marketing Leadership

Anju Starace
Anju Starace
Associate Vice President, US Marketing, CNS
At the company for 12 years 9 months
Vijay Raghavan
Vijay Raghavan
Associate Vice President Marketing Analytics & Business Insights
At the company for 9 years 9 months
Chrissy Wild
Chrissy Wild
Head of Marketing - Lupron
At the company for 8 years 1 month
Anna Begley
Anna Begley
Head of Marketing, UBRELVY
At the company for 6 years 4 months

Funding

Total Funding
$23B
Last Raise
$8B
Post IPO Debt, 18 days ago

Funding History

  • Feb 2026
    Post IPO Debt • $8B
  • Feb 2024
    Post IPO Debt • $15B
  • Mar 2023
    Post IPO Equity • $250K

Traffic Signals

Monthly Visitors
1.4M
Monthly Google Ads Budget
$37.3K
Traffic Source Mix
Search
35%
Direct
45.7%
Referral
11.2%
Social
6.1%
Paid
1.8%

Headcount Trend

Current headcount: ~59.9K

Recent News

UPDATED: AbbVie to end Calico collab after 11-year run, plans layoffs: Stat
Nov 13, 2025 • Fierce Biotech
AbbVie Ends 11-Year Relationship With Calico, Lays Off 100+
Nov 13, 2025 • BioSpace
AbbVie cuts ties with Google-backed longevity company, lays off scientists
Nov 12, 2025 • statnews.com
Jim Cramer Says “I Found the AbbVie Call Particularly Jarring”
Nov 5, 2025 • Yahoo Finance
Analyst on AbbVie (ABBV): ‘Stay Long’
Nov 3, 2025 • Yahoo Finance
Why AbbVie Stock Flopped on Friday
Nov 1, 2025 • The Motley Fool
AbbVie Beats Third-Quarter Estimates. There’s More to the Drugmaker’s Earnings.
Oct 31, 2025 • Barron's
AbbVie boosts revenue forecast by $400M thanks to booming sales of Skyrizi, Rinvoq
Oct 31, 2025 • Fierce Pharma
AbbVie Inc (ABBV) Q3 2025 Earnings Call Highlights: Strong Financial Performance Amidst Humira ...
Oct 31, 2025 • Yahoo Finance
How the Story for AbbVie Is Evolving After Key Pipeline Wins and Analyst Shifts
Oct 25, 2025 • Yahoo Finance
Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for
Oct 24, 2025 • Yahoo Finance
AbbVie's Rinvoq shows superiority over Humira in head-to-head arthritis study
Oct 20, 2025 • Reuters
AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
Oct 13, 2025 • PR Newswire
How pharma giant AbbVie holds leaders accountable for culture
Oct 9, 2025 • Fortune
Why AbbVie Stock Soared in September
Oct 8, 2025 • The Motley Fool
AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?
Oct 6, 2025 • Yahoo Finance
AbbVie breaks ground on $70m US biologics site amid Trump pressure
Oct 1, 2025 • Pharmaceutical Technology
Why AbbVie Stock Cruised to an Almost 6% Gain Today
Oct 1, 2025 • The Motley Fool
AbbVie charts next leg of US investment journey with $70M expansion in MA
Oct 1, 2025 • Fierce Pharma
AbbVie to launch ovarian cancer drug in UK at US price
Sep 29, 2025 • Reuters
REGENXBIO Announces Presentation at the World Muscle Society
Sep 29, 2025 • PR Newswire
AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
Sep 29, 2025 • PR Newswire
United States Cancer Therapeutics Market to Hit $491.6 Billion by 2032, Driven by Precision and Immunotherapy Advances
Sep 29, 2025 • EIN Presswire
September’s FDA Action Bolsters Keytruda, Ultra-Rare Disease but Deals Two SMA Defeats
Sep 29, 2025 • BioSpace
AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson’s Disease
Sep 29, 2025 • BioSpace
AbbVie to launch ovarian cancer drug in UK at the same list price as US
Sep 29, 2025 • MarketScreener
Mosaic Consulting Expands Salesforce and Braze Services, Showcases Software Expertise with DrugAlert.ai
Sep 29, 2025 • PR Newswire
AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
Sep 29, 2025 • PR Newswire
AbbVie to launch ovarian cancer drug in UK at US price
Sep 29, 2025 • Investing.com
AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
Sep 29, 2025 • MarketScreener
District court denies preliminary injunctions by drug companies in challenges to Maine’s 340B contract pharmacy law
Sep 24, 2025 • American Hospital Association
FDA’s Autism Endeavor, Pfizer’s Obesity Comeback Bid, Psychedelics Revival, ACIP Confusion, More
Sep 24, 2025 • BioSpace
Glenmark inks $18 million deal for cancer drug with China’s Hengrui
Sep 24, 2025 • Livemint.com
Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies
Sep 24, 2025 • Benzinga.com
Care and Commitment: Celebrating AbbVie's 2025 Working Parents/Caregivers
Sep 23, 2025 • AbbVie
Vernon Hills office hits market as landlord scrambles to cover loan
Sep 23, 2025 • The Real Deal
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
Sep 23, 2025 • MarketScreener
Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality
Sep 23, 2025 • PR Newswire
Allergan Aesthetics, an AbbVie company Announces Expansion of SKINVIVE by JUVEDERM into 35 New Markets
Sep 23, 2025 • MarketScreener
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
Sep 23, 2025 • Amneal Pharmaceuticals LLC
AbbVie to Launch Skinvive in 35 Additional Markets
Sep 23, 2025 • MarketScreener
Allergan Aesthetics to Launch Skinvive in 35 New Markets
Sep 23, 2025 • Orange County Business Journal
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
Sep 22, 2025 • BioSpace
Parkinson's Disease Therapeutics Market Size to Hit US$ 12.83 Billion by 2033, Report by DataM Intelligence
Sep 22, 2025 • PR Newswire
1 Top Dividend Stock to Buy and Hold Forever
Sep 22, 2025 • The Motley Fool
What Is One of the Best Pharmaceutical Stocks to Buy Right Now?
Sep 22, 2025 • The Motley Fool
Psychedelics Space Enters New Era as AbbVie Dives In
Sep 22, 2025 • BioSpace
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
Sep 19, 2025 • Morningstar.com
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
Sep 19, 2025 • MarketScreener
BMO Lifts AbbVie Inc. (ABBV) Price Target to $240 After Rinvoq Litigation Win
Sep 18, 2025 • Yahoo Finance
Roche Makes Major MASH Move With $3.5B 89bio Buy
Sep 18, 2025 • BioSpace
AbbVie just upgraded at Berenberg, here's why
Sep 17, 2025 • thefly.com
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Sep 17, 2025 • Benzinga.com
Berenberg sees opportunity for pharma cos despite policy risks; upgrades Novo
Sep 17, 2025 • Reuters
AbbVie price target raised by $35 at JPMorgan, here's why
Sep 16, 2025 • thefly.com
AbbVie Settles Rinvoq Litigation, Blocks Generics Until 2037
Sep 16, 2025 • Law360
Novo amylin drug underperforms Wegovy in efficacy, but scores in tolerability
Sep 16, 2025 • FierceBiotech
Genmab discards clinical ADC picked up in last year's $1.8B ProfoundBio buy
Sep 16, 2025 • FierceBiotech
Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility
Sep 16, 2025 • Morningstar.com
FDA targets Lilly, Novartis, BMS and more in deluge of marketing letters
Sep 16, 2025 • FiercePharma
Maricel Torrent Recognized by Influential Women 2025
Sep 15, 2025 • EIN Presswire
Saisei Ventures Appoints James Feliciano as Venture Partner
Sep 15, 2025 • Venture Capital Firms
AbbVie broadens its telisotuzumab conjugate push | ApexOnco - Clinical Trials news and analysis
Sep 12, 2025 • Oncology Pipeline
AbbVie Adds Four Years of Exclusivity to Rinvoq Franchise With Generics Settlement
Sep 12, 2025 • BioSpace
Dow Jones Top Company Headlines at 9 PM ET: Microsoft, OpenAI Truce Clears Hurdle in Path to For-Profit Conversion | Adobe ...
Sep 12, 2025 • Morningstar.com
Wells sees AbbVie Rinvoq settlement being worth $11-$24 per share
Sep 11, 2025 • thefly.com
AbbVie price target raised by $25 at BMO Capital, here's why
Sep 11, 2025 • thefly.com
AbbVie in Settlement With Generic Drugmakers on Rinvoq
Sep 11, 2025 • Morningstar.com
AbbVie shares hit record high as key immunology drug set for exclusivity until 2037
Sep 11, 2025 • MarketScreener
AbbVie stock rises after securing patent protection for RINVOQ until 2037
Sep 11, 2025 • Yahoo Finance - Business Finance, Stock Market, Quotes, News
Dow Jones Top Company Headlines at 3 PM ET: Paramount Skydance Prepares Ellison-Backed Bid for Warner Bros. Discovery | AbbVie ...
Sep 11, 2025 • Morningstar.com
AbbVie On Pace For Record High Close — Data Talk
Sep 11, 2025 • Morningstar.com
AbbVie jumps 4% to $220.77 after settling with Rinvoq generic makers
Sep 11, 2025 • thefly.com
Dow Jones Top Company Headlines at 3 PM ET: Paramount Skydance Prepares Ellison-Backed Bid for Warner Bros. Discovery | AbbVie ...
Sep 11, 2025 • Dow Jones Newswires
Glenmark gains 3% on $700 mn upfront payment from AbbVie licensing deal
Sep 9, 2025 • Business Standard India
BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories
Sep 9, 2025 • PR Newswire
Glenmark Pharma shares rise as arm receives an upfront payment of $700 mn
Sep 9, 2025 • Business Standard India
Transcript : AbbVie Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-09-2025 10
Sep 9, 2025 • MarketScreener
Glenmark Pharma subsidiary IGI gets $700 million upfront payment from AbbVie
Sep 9, 2025 • Hindu Business Line
1 Reason Every Investor Should Know About AbbVie (ABBV)
Sep 8, 2025 • The Motley Fool
"Anti-Parkinson's Drugs: Global Markets to 2030"
Sep 8, 2025 • PharmiWeb
Trump’s factory boom stalled for now as payrolls keep shrinking
Sep 6, 2025 • Boston Herald
Run. Rally. Rise. The 2025 Race to End Women's Cancer is Back in Washington, D.C.
Sep 5, 2025 • PR Newswire
AbbVie and Genmab’s Epkinly shows outpatient viability in Phase II trial
Sep 4, 2025 • Clinical Trials Arena
Don't miss out on these 2 stocks, say analysts at MOFSL; details inside
Sep 4, 2025 • Business Standard India
After 2021 SPAC Bubble, How Did These 6 Biotechs Fare?
Sep 3, 2025 • BioSpace
Antitrust Softens, Yields Still Rise
Sep 3, 2025 • MarketScreener
AbbVie reports results from Phase 2 EPCORE NHL-6 trial
Sep 3, 2025 • thefly.com
Genmab Announces Updated Results from Phase 2 EPCORE® NHL...
Sep 3, 2025 • PharmiWeb
Global drugmakers rush to boost US presence as tariff threat looms
Sep 3, 2025 • MarketScreener
Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid (HA) Injectable Fillers
Sep 3, 2025 • PR Newswire
Multiple Myeloma Market Size Projected USD 49.89 Billion by 2034
Sep 3, 2025 • Precedence Research
AbbVie Gets Health Canada Approval for Ovarian-Cancer Treatment
Sep 2, 2025 • MarketScreener
Health Canada Approves ELAHERE® for Certain Types of Platinum-Resistant Ovarian Cancers Français
Sep 2, 2025 • Canada NewsWire
AbbVie Says Health Canada Approves Elahere in Some Types of Ovarian Cancers
Sep 2, 2025 • MarketScreener
AbbVie Named to 2025 Best Workplaces in Asia List by Great Place To Work
Sep 1, 2025 • prnasia.com
JLS Fund Congratulates Largest Portfolio Holding, Gilamesh Pharmaceuticals on $1.2 Billion Deal with AbbVie (NYSE: ABBV)
Sep 1, 2025 • EIN Presswire
Blood Cancer Awareness Month: What biotech holds in store
Sep 1, 2025 • Labiotech.eu
5 High-Yield Dividend Stocks I Plan on Holding for the Next 10 Years or Longer
Aug 31, 2025 • The Motley Fool
Great Place to Work Middle East announces the 2025 Best Workplaces in Asia
Aug 30, 2025 • Zawya.com

Links

www.abbvie.comLinkedInX (Twitter)Crunchbase